Izervay (avacincaptad pegol sodium/PF)

Dosage of avacincaptad pegol sodium is expressed in terms of avacincaptad pegol.

No dosing information is available for this tab.

No dosing information is available for this tab.

Formal drug interaction studies have not been conducted with avacincaptad pegol.

There are no contraindication interactions for this drug.

There are no severe interactions for this drug.

There are no moderate interactions for this drug.

*Ocular or periocular infections.

*Active intraocular inflammation.

• Ocular infection

• Ocular inflammation

There are no moderate contraindications for this drug.

The most common adverse reactions reported with avacincaptad pegol in clinical studies were conjunctival hemorrhage (13%), increased IOP (9%), blurred vision (8%), and neovascular age-related macular degeneration (7%).

More Frequent

• Neovascular age-related macular degeneration
• Ocular hypertension

Rare or Very Rare

• Endophthalmitis
• Photopsia
• Retinal detachment
• Vitreous hemorrhage
• Vitritis

More Frequent

• Blurred vision
• Conjunctival hemorrhage

Less Frequent

• Blepharitis
• Ocular pain
• Vitreous floater

No enhanced messaging available.

The safety and efficacy of avacincaptad pegol in pediatric patients have not been established.

There are no adequate data regarding the use of avacincaptad pegol in pregnant women. Use of avacincaptad pegol in pregnancy may be considered following an assessment of the risks and benefits. No maternal or embryofetal adverse effects were observed in animal studies; however, in rat studies, an increase in the incidence of non-adverse skeletal variation, described as short thoracolumbar supernumerary ribs was observed.

It is not known whether avacincaptad pegol is distributed into human milk, or if the drug has any effects on the breastfed infant or on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for avacincaptad pegol, and any potential adverse effects on the breastfed infant from the drug or underlying maternal condition.

Dosage adjustments are not needed in geriatric patients.

Among the patients who received avacincaptad pegol in clinical studies, 90% were >=65 years of age and 61% were >=75 years of age. No differences in efficacy or safety of avacincaptad pegol were observed with increasing age, and no dosage adjustments are recommended based on age.